Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis

Journal of Attention Disorders

Volumn 15, Issue 8, 2011, Pages 674-683

  Hazell, Philip L ^a   Kohn, Michael R ^b   Dickson, Ruth ^c   Walton, Richard J ^d   Granger, Renee E ^d   van Wyk, Gregory W ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ELI LILLY AND COMPANY   (United States)

^d ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

ADHD; atomoxetine; child; meta analysis; methylphenidate

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; PROPYLAMINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 82455186436     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054710379737     Document Type: Article

References (29)

1. Altman D.G.Confidence intervals for the number needed to treat.British Medical Journal. 1998;317:1309-1312.
2. American Psychiatric Association (APA). (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC, Author.
3. Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., . . . Perry, K. W. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711.
4. Committee for Proprietary Medicinal Products. (2004). Point to consider on clinical investigation of medicinal products used in the treatment of nociceptive pain. Retrieved April 7, 2009, from http://www.tga.gov.au/docs/pdf/euguide/ewp/078497en.pdf.
5. Cook R.J.,Sackett D.L.The number needed to treat: A clinically useful measure of treatment effect.British Medical Journal. 1995;310:452-454.
6. DuPaul G.J.,Power T.J.,Anastopoulos A.D.,Reid R.ADHD Rating Scale-IV. Checklist, norms, and clinical interpretations. New York, NY: Guilford; 1998:.
7. Egger M.,Smith G.D.Meta-analysis bias in location and selection of studies.British Medial Journal. 1998;316:61-66.
8. Faries D.E.,Yalcin D.,Harder D.,Heiligenstein J.H.Validation of the ADHD Rating Scale as a clinician-administered and scored instrument.Journal of Attention Disorders. 2001;5:107-115.
9. Gao, H., Zhao, Y., Levine, L., & Allen, A. (2006). Determining cut-points for clinically meaningful improvement: A receiver operating characteristic approach. Scientific Proceedings of the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, pp. 201, Washington, DC: American Academy of Child and Adolescent Psychiatry.
10. Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V., . . . Sumner, C. (2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 1119-1127.
11. Guy W.ECDEU assessment manual for psychopharmacology, revised. Bethesda, MD: US Department of Health, Education, and Welfare; 1976:.
12. Hazell P.,Lewin T.,Sly K.What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder?.Australian and New Zealand Journal of Psychiatry. 2005;39:354-358.
13. Heil S.H.,Holmes H.W.,Bickel W.K.,Higgins S.T.,Badger G.J.,Laws H.F., et al.Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.Drug and Alcohol Dependence. 2002;67:149-156.
14. Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., . . . Allen, A. J. (2004). Oncedaily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, e1-8.
15. Kemner J.E.,Starr H.L.,Ciccone P.E.,Hooper-Wood C.G.,Crockett R.S.Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study.Advanced Therapeutics. 2005;22:498-512.
16. Kratochvil, C. J., Heiligenstein, J. H., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J., . . . Michelson, D. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 776-784.
17. Lopez F.A.ADHD: New pharmacological treatments on the horizon.Journal of Developmental & Behavioral Pediatrics. 2006;27:410-416.
18. Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., . . . Harder, D. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901
19. Newcorn J.H.,Kratochvil C.J.,Allen A.J.,Casat C.D.,Ruff D.D.,Moore R.J.Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response.American Journal of Psychiatry. 2008;165:721-730.
20. Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., . . . Morse, G. D. (2001). Oncea-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, e105.
21. Pliszka, S. R., Crismon, M. L., Hughes, C. W., Corners, C. K., Emslie, G. J., Jensen, P. S., . . . Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. (2006). The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 642-657.
22. Polanczyk G.,de Lima M.S.,Horta B.L.,Biederman J.,Rohde L.A.The worldwide prevalence of ADHD: A systematic review and metaregression analysis.American Journal of Psychiatry. 2007;164:942-948.
23. Prasad S.,Harpin V.,Poole L.,Zeitlin H.,Jamdar S.,Puvanendran K.A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).Current Medical Research & Opinion. 2007;23:379-394.
24. Sangal R.B.,Owens J.,Allen A.J.,Sutton V.,Schuh K.,Kelsey D.Effects of atomoxetine and methylphenidate on sleep in children with ADHD.Sleep. 2006;29:1573-1585.
25. Spencer T.,Heiligenstein J.H.,Biederman J.,Faries D.E.,Kratochvil C.J.,Conners C.K.,Potter W.Z.Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.Journal of Clinical Psychiatry. 2002;63:1140-1147.
26. Spencer, T. J., Sallee, F. R., Gilbert, D. L., Dunn, D. W., McCracken, J. T., Coffey, B. J., . . . Mintz, M. (2008). Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders, 11, 470-481.
27. Starr H.L.,Kemner J.Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD.Journal of the National Medical Association. 2005;97:11S-16S.
28. Steele M.,Jensen P.S.,Quinn D.M. P.Remission versus response as the goal of therapy in ADHD: A new standard for the field?.Clinical Therapeutics. 2006;28:1892-1908.
29. Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y. J., Cho, S. C., . . . Levine, L. R. (2007). Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Australian and New Zealand Journal of Psychiatry, 41, 222-230.